Prothionamide and prothionamide-S-oxide in experimental leprosy.
D000818:Animals; D007539:Isonicotinic Acids / Q000627:therapeutic use*; D007917:Leprostatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009166:Mycobacterium leprae / Q000187:drug effects; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009536:Niacinamide / Q000031:analogs & derivatives / Q000494:pharmacology; D011515:Prothionamide / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*
D007539:Isonicotinic Acids; D007917:Leprostatic Agents; D009536:Niacinamide; C033377:prothionamide-S-oxide; D011515:Prothionamide; C033376:2-propylisonicotinamide